1. Research Methodology

2. US Transdermal Patch Market Outlook

2.1 Approved Transdermal Patches Insight

2.2 Current Market Scenario

2.3 Favorable Market Growth Inhibitors

2.4 Clinical and Commercialization Challenges

2.5 Future Marketing Opportunities

3. Branded vs Generic Transdermal Patches Comparison

4. Transdermal Patch Clinical and Market Trends By Indication

  4.1 Brain, Neurological and Psychotic Disorders

  4.2 Hormone Modulators

  4.2.1 Hormone Replacement Therapies (HRT)

  4.2.2 Contraception

  4.3 Diabetes

  4.4 Vaccine

  4.5 Substance Use Disorders

  4.6 Cardiovascular Diseases

5. US Transdermal Patch Clinical Pipeline Overview

  5.1 By Company

  5.2 By Drug Class

  5.3 By Indication

  5.4 By Phase

  5.5 By Priority Status

6. Cardiovascular Diseases Transdermal Patch - US Market Availability, Dosage and Price Analysis

  6.1 Clonidine Transdermal Patch

  6.2 Nitroglycerin Transdermal Patch

7. Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage and Price Analysis

  7.1 Fentanyl Transdermal Patch

  7.2 Buprenorphine Transdermal Patch

8. Neurological Disorders Transdermal Patch - US Market Availability, Dosage and Price Analysis

  8.1 Selegiline Transdermal Patch

  8.2 Rivastigmine Transdermal Patch

  8.3 Methylphenidate Transdermal Patch

  8.4 Asenapine Transdermal Patch

  8.5 Rotigotine Transdermal Patch (Neupro) sales

  8.6 Donepezil Transdermal Patch

  8.7 Dextroamphetamine Transdermal Patch

9. Hormonal Therapy Transdermal Patch - US Market Availability, Dosage and Price Analysis

  9.1 Estradiol Transdermal Patch

  9.2 Testosterone Transdermal Patch (Androderm)

10. Transdermal Patches for Other Conditions - US Market Availability, Dosage and Price Analysis

  10.1 Nicotine Transdermal Patch

  10.2 Oxybutynin Transdermal Patch

  10.3 Granisetron Transdermal Patch (Sancuso)

11. US Transdermal Patch Clinical Trials Insight By Company, Indication and Phase

  11.1 Research

  11.2 Preclinical

  11.3 Phase-I

  11.4 Phase-II

  11.5 Phase-III

  11.6 Preregistration

  11.7 Registered

12. US Commercially Available Transdermal Patches Clinical Insight by Indication

13. Competitive Landscape

  13.1 AbbVie

  13.2 AFYX Therapeutics

  13.3 Agile Therapeutics

  13.4 Bayer HealthCare Pharmaceuticals

  13.5 Corsair Pharma

  13.6 DBV Technologies

  13.7 Hisamitsu Pharmaceutical

  13.8 IBSA

  13.9 Privo Technologies

  13.10 Psilera

  13.11 Starton Therapeutics

  13.12 Teikoku Pharma USA

  13.13 Teikoku Seiyaku

  13.14 UCB

  13.15 Vaxess Technologiess

  13.16 Verndari

 Figure 2-1: Advantages of Transdermal Patches

 Figure 2-2: Disadvantages of Transdermal Patches

 Figure 2-3: US - Transdermal Patch Market (US$ Billion), 2021 - 2029

 Figure 2-4: Transdermal Patch Market Favorable Factors

 Figure 2-5: Transdermal Patch Market Commercialization Challenges

 Figure 3-1: Nitroglycerin - Branded v/s Generic Version Costs for Different Doses

 (US$), September’2023

 Figure 3-2: Nitroglycerin - Branded v/s Generic Version Percentage Decrease in Cost,

 September’2023

 Figure 3-3: Implications of Branded vs Generic Competition

 Figure 4-1: Potential Market Segments of Transdermal Drug Delivery Systems

 Figure 4-2: NCT03740204 Phase 2 Study – Initiation and Completion Years

 Figure 4-3: DepMIND3 Phase 2 Study – Initiation and Completion Years

 Figure 4-4: NCT05704036 Phase 2 Study – Initiation and Completion Years

 Figure 4-5: NCT03875378 Phase 2 Study – Initiation and Completion Years

 Figure 4-6: Requirements of Female Contraceptive Transdermal Patches

 Figure 4-7: Benefits of Female Contraceptive Transdermal Drug Delivery System

 Figure 4-8: Benefits of Insulin Transdermal Patch

 Figure 4-9: Drawbacks of Insulin Transdermal Patch

 Figure 4-10: Benefits of Vaccine Transdermal Patch

 Figure 4-11: Drawbacks of Vaccine Transdermal Patch

 Figure 4-12: Factors Responsible for Increased Consumption of Nicotine Patches

 Figure 4-13: NCT05886582 Phase 2 Study – Initiation and Completion Years

 Figure 5-1: US - Transdermal Patch Pipeline by Company (Numbers), 2023 till 2029

 Figure 5-2: US Transdermal Patch Pipeline by Drug Class (Numbers), 2023 till 2029

 Figure 5-3: US Transdermal Patch Pipeline by Indication (Numbers), 2023 till 2029

 Figure 5-4: US Transdermal Patch Pipeline by Phase (Numbers), 2023 till 2029

 Figure 5-5: US Transdermal Patch Pipeline by Priority Status (Numbers), 2023 till 2029

 Figure 6-1: Catapres – FDA Approval, First Generic Approval and Branded Drug

 Discontinuation Years

 Figure 6-2: Generic Clonidine Patch - Price per Unit and Supply of Different Doses (US$),

 September’2023

 Figure 6-3: Clonidine Transdermal Patch – Recommended Initial, Incremented and

 Maximum Doses (mg/week)

 Figure 6-4: Clonidine Transdermal Patch – Monthly and Annual Treatment Costs (US$),

 September’2023

 Figure 6-5: Nitro-Dur – Price per Unit and Supply of Different Doses (US$),

 September’2023

 Figure 6-6: Generic Nitroglycerin Transdermal Patch – Price per Unit and Supply of

 Different Doses (US$), September’2023

 Figure 7-1: Duragesic – FDA Approval, First Generic Approval and Branded Drug

 Discontinuation Years

 Figure 7-2: Generic Fentanyl Transdermal Patch - Price per Unit and Supply of Different

 Doses (US$), September’2023

 Figure 7-3: Butrans - Price per Unit and Supply of Different Doses (US$), September’2023

 Figure 7-4: Generic Buprenorphine Transdermal Patch - Price per Unit and Supply of

 Different Doses (US$), September’2023

 Figure 8-1: Emsam - Price per Unit and Supply (US$), September’2023

 Figure 8-2: Emsam - Monthly and Annual Treatment Costs (US$), September’2023

 Figure 8-3: Exelon – Price per Unit and Supply (US$), September’2023

 Figure 8-4: Generic Rivastigmine Transdermal Patch – Price per Unit and Supply (US$),

 September’2023

 Figure 8-5: Exelon – Initial and Maintenance Dose for Treatment of Parkinson’s disease

 Figure 8-6: Exelon – Monthly and Annual Treatment Costs for Parkinson’s disease (US$),

 September’2023

 Figure 8-7: US – Daytrana Patent Issue and Expiration Year

 Figure 8-8: Daytrana - Price per Unit and Supply of All Doses (US$), September’2023

 Figure 8-9: US – Secuado Patent Issue and Expiration Years

 Figure 8-10: Secuado – Price per Unit and Supply of All Doses (US$), September’2023

 Figure 8-11: Secuado – Recommended Initial and Incremented Dose (mg/Day)

 Figure 8-12: US – Neupro Patent Issue and Expiration Years

 Figure 8-13: Neupro – Price per Unit and Supply (US$), September’2023

 Figure 8-14: Neupro – Initial and Maximum Recommended Doses for Early-Stage and

 Advanced Parkinson’s disease (mg/day)

 Figure 8-15: Neupro – Initial and Maximum Recommended Dose for Restless Leg

 Syndrome (mg/day)

 Figure 8-16: US – Neupro Annual Sales (US$ Million), 2019-2022

 Figure 8-17: Global – Neupro Annual Sales (US$ Million), 2019-2023*

 Figure 8-18: US – Adlarity Patent Issue and Expiration Years

 Figure 8-19: Adlarity - Price per Unit and Supply for All Doses (US$), September’2023

 Figure 8-20: Adlarity – Recommended Initial and Incremented Dose (mg/day)

 Figure 8-21: Adlarity – Monthly and Yearly Treatment Costs (US$), September’2023

 Figure 8-22: US – Xelstrym Patent Issue and Expiration Years

 Figure 8-23: Xelstrym - Price per Unit and Supply for All Doses (US$), September’2023

 Figure 8-24: Xelstrym – Recommended Initial and Maximum Doses for Pediatric and Adult

 Patients (mg/day)

 Figure 9-1: Vivelle-Dot – FDA Branded and First Generic Approval Years

 Figure 9-2: Vivelle-Dot - Price per Unit and Supply of Different Doses (US$),

 September’2023

 Figure 9-3: Recommended Doses for Treatment of Vaginal Atrophy, Vasomotor

 Symptoms, and Postmenopausal Osteoporosis (mg/Day)

 Figure 9-4: Minivelle – FDA Branded and First Generic Approval Years

 Figure 9-5: US – Minivelle Patent Issue and Expiration YearS

 Figure 9-6: Minivelle – Price per Unit and Supply of All Doses (US$), September’2023

 Figure 9-7: Minivelle - Recommended Dose by Indication (mg/Day)

 Figure 9-8: Climara – FDA Branded and First Generic Approval Years

 Figure 9-9: Climara – Price per Unit and Supply of Various Doses (US$), September’2023

 Figure 9-10: Menostar – FDA Branded and First Generic Approval Years

 Figure 9-11: Menostar – Price per Unit and Supply (US$), September’2023

 Figure 9-12: Climara Pro – Price per Unit and Supply (US$), September’2023

 Figure 9-13: CombiPatch – Price per Unit and Supply of Both Doses (US$),

 September’2023

 Figure 9-14: Xulane – Price per Unit and Supply (US$), September’2023

 Figure 9-15: Xulane – Recommended Schedule for Achieving Birth Control Effect (Days)

 Figure 9-16: Zafemy – Price per Unit and Supply (US$), September’2023

 Figure 9-17: US – Twirla Patent Issue and Expiration Year

 Figure 9-18: Twirla – Price per Unit and Supply (US$), September’2023

 Figure 9-19: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)

 Figure 9-20: Generic Estradiol Transdermal Patch – Price per unit and Supply (US$),

 September’2023

 Figure 9-21: Androderm – Price per Unit and Supply (US$), September’2023

 Figure 9-22: Androderm – Recommended Initial and Maintainence Dose for Treatment of

 Hypogonadism (mg/day)

Figure 10-1: Nicoderm CQ – Price per Unit and Supply of 7mg and 14mg Transdermal Patches (US$), September’2023

 Figure 10-2: Nicoderm CQ – Price per Unit and Supply of 21mg Transdermal Patches

 (US$), September’2023

 Figure 10-3: Nicoderm CQ – Recommended Dose and Treatment Schedule for Patients

 with Consumption of >10 Cigarette/Day (mg/day)

 Figure 10-4: Nicoderm CQ – Recommended Dose and Treatment Schedule for Patients

 with Consumption of andlt;10 Cigarette/Day (mg/day)

 Figure 10-5: Nicoderm CQ – Full Treatment Cost for Patients with Daily Consumption

 of andlt;10 Cigarettes and >10 Cigarettes (US$), September’2023

 Figure 10-6: Habitrol – Price per Unit and Supply (US$), September’2023

 Figure 10-7: Habitrol – Recommended Dose and Treatment Schedule for Patients with

 Consumption of >10 Cigarettes/Day (mg/day)

 Figure 10-8: Habitrol – Recommended Dose and Treatment Schedule for Patients with

 Consumption of andlt;10 Cigarettes/Day (mg/day)

 Figure 10-9: Habitrol – Full Treatment Cost for Patients with Daily Consumption of andlt;10

 Cigarettes and >10 Cigarettes (US$), September’2023

 Figure 10-10: Generic Nicotine Transdermal Patch – Price per Unit and Supply of Dose

 7mg (US$), September’2023

 Figure 10-11: Generic Nicotine Transdermal Patch – Price per Unit and Supply of Dose

 14mg (US$), September’2023

 Figure 10-12: Generic Nicotine Transdermal Patch – Price per Unit and Supply of Dose

 21mg (US$), September’2023

 Figure 10-13: Oxytrol – Price per Unit and Supply (US$), September’2023

 Figure 10-14: Oxytrol for Women – Price per Unit and Supply (US$), September’2023

 Figure 10-15: Sancuso – Patent Issue and Expiration Year

List of Tables

Table 2-1: US – Currently Available Branded Transdermal Patches

Table 2-2: Features Required in Transdermal Patches

Table 3-1: Comparison of Features of Branded and Generic Patches

Table 7-1: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage

Table 8-1: Daytrana - Recommended Titration Schedule for ADHD Treatment